We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+19.78%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$251M
AUM Growth
+$35.9M
Cap. Flow
+$5.21M
Cap. Flow %
2.07%
Top 10 Hldgs %
49.32%
Holding
52
New
14
Increased
11
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
AFMD
Affimed
AFMD
+$5.67M
2
HROW icon
Harrow
HROW
+$4.22M
3
AXGN icon
Axogen
AXGN
+$3.66M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$3.26M
5
KYNB
Kyntra Bio
KYNB
+$3.11M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.49M
2
CMRX
Chimerix, Inc.
CMRX
+$5.01M
3
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$4.5M
4
KITE
Kite Pharma, Inc.
KITE
+$4.38M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$4.28M

Sector Composition

Rank Sector Weight
1 Healthcare 94.46%
2 Miscellaneous 5.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
1
DELISTED
Chimerix, Inc.
CMRX
$20.3M 8.09%
440,000
-125,000
-22% -$5.01M
CEMP
2
DELISTED
Cempra, Inc.
CEMP
$16.8M 6.7%
490,000
-10,000
-2% -$354K
TVTX icon
3
Travere Therapeutics
TVTX
$6.36B
$15.2M 6.07%
460,000
-40,000
-8% -$1.1M
AMAG
4
DELISTED
AMAG Pharmaceuticals
AMAG
$13.1M 5.22%
190,000
– –
ARIA
5
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$12.4M 4.94%
1,500,000
– –
RARE icon
6
Ultragenyx Pharmaceutical
RARE
$2.59B
$11.3M 4.48%
110,000
– –
HROW icon
7
Harrow
HROW
$1.44B
$9.8M 3.9%
1,205,000
+517,900
+75% +$4.22M
SUPN icon
8
Supernus Pharmaceuticals
SUPN
$2.57B
$9.08M 3.61%
535,000
– –
AFMD
9
DELISTED
Affimed
AFMD
$7.95M 3.16%
+59,030
New +$5.67M
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
$7.91M 3.15%
90,000
-50,000
-36% -$4.28M
GERN icon
11
Geron
GERN
$983M
$7.81M 3.11%
1,825,000
– –
KYNB
12
Kyntra Bio
KYNB
$32.4M
$7.64M 3.04%
13,000
+5,346
+70% +$3.11M
MDXG icon
13
MiMedx Group
MDXG
$657M
$7.15M 2.85%
617,000
+27,000
+5% +$278K
NBIX icon
14
Neurocrine Biosciences
NBIX
$15.8B
$6.92M 2.76%
145,000
– –
CDXS icon
15
Codexis
CDXS
$182M
$6.71M 2.67%
1,724,000
– –
AXGN icon
16
Axogen
AXGN
$2.78B
$6.66M 2.65%
2,120,000
+1,134,100
+115% +$3.66M
AVDL
17
DELISTED
Avadel Pharmaceuticals
AVDL
$6.57M 2.61%
310,000
+10,000
+3% +$179K
GNMX
18
DELISTED
Aevi Genomic Medicine Inc
GNMX
$6.44M 2.56%
1,050,000
+200,000
+24% +$1.55M
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.49M 2.18%
105,000
– –
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
$5.46M 2.17%
250,000
-10,000
-4% -$228K
ZSPH
21
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$4.98M 1.98%
95,000
+20,000
+27% +$985K
AMRN
22
Amarin Corp
AMRN
$297M
$4.32M 1.72%
87,700
– –
TVRD
23
Tvardi Therapeutics
TVRD
$24M
$4.13M 1.64%
9,444
+694
+8% +$268K
EGRX
24
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4.04M 1.61%
+50,000
New +$3.26M
ADMS
25
DELISTED
Adamas Pharmaceuticals
ADMS
$3.93M 1.56%
150,000
-105,000
-41% -$2.04M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2015 Portfolio in Review

As of Q2 2015, Opaleye Management held 52 positions worth $251M, up 17% from $215M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management's Q2 2015 filing shows 14 new, 11 increased, 9 reduced and 5 closed positions. Its largest new stake was Affimed: 59,030 shares worth $7.95M. The largest sale was Agios Pharmaceuticals, an estimated $8.49M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q2 2015 buy was Affimed: 59,030 shares worth $7.95M.
  • Opaleye Management added most to Harrow in Q2 2015, an estimated $4.22M increase.
  • Opaleye Management's biggest Q2 2015 reduction was Chimerix, Inc., cutting an estimated $5.01M.
  • Opaleye Management fully exited Agios Pharmaceuticals in Q2 2015, selling an estimated $8.49M.
  • Opaleye Management's ten largest holdings make up 49% of its $251M portfolio in Q2 2015.
  • Opaleye Management opened 14 new positions and closed 5 in Q2 2015.
  • Opaleye Management's portfolio value rose 17% quarter-over-quarter to $251M.

Based on Opaleye Management's 13F filing for Q2 2015, filed 14 Aug 2015.